Glucagon-like Peptide 1 Market Report 2026

Glucagon-like Peptide 1 Market Overview

• Glucagon-like Peptide 1 market size has reached to $22.06 billion in 2025 • Expected to grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Growing Health Awareness Fuels Demand For Glucagon-Like Peptide 1 (GLP-1) Market • Market Trend: Novo Nordisk Introduces Wegovy Therapy For Weight Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glucagon-like Peptide 1 Market?

Glucagon-like peptide 1 refers to a type of amino acid hormone of peptide that is produced in the L-cells of the intestinal epithelial endocrine. Glucagon-like peptide 1 is used to treat diseases and conditions such as diabetes and obesity respectively. The main glucagon-like peptide 1 product types are trulicity, ozempic, victoza, rybelsus, and others. Trulicity refers to a prescription medicine that is injectable and is used to improve blood sugar. The various routes of administration are oral, parenteral, and others used in hospitals, specialty clinics, and others.

What Is The Glucagon-like Peptide 1 Market Growth Forecast?

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for weight management therapies, rising investments in peptide drug innovation, expansion of oral peptide delivery technologies, growing focus on chronic disease management, increasing adoption of personalized medicine. Major trends in the forecast period include rising adoption of GLP-1 therapies for obesity management, increasing development of oral glp-1 formulations, growing focus on long-acting peptide drugs, expansion of combination therapy approaches, enhanced patient-centric drug delivery systems.

Global Glucagon-like Peptide 1 Market Segmentation

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types 2) By Route of Administration: Oral, Parenteral, Other Routes 3) By End-Users: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.) 2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.) 3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.) 4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg) 5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

What Is The Driver Of The Glucagon-like Peptide 1 Market?

Increasing emphasis on personalized medicine is expected to propel the growth of the glucagon-like peptide 1 (GLP-1) market going forward. Personalized medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's genes or proteins. Personalized medicine allows for the tailoring of GLP-1 formulations and dosages based on individual patient needs and preferences. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing emphasis on personalized medicine is driving the growth of the glucagon-like peptide 1 (GLP-1) market.

What Is The Driver Of The Glucagon-like Peptide 1 Market?

Increasing emphasis on personalized medicine is expected to propel the growth of the glucagon-like peptide 1 (GLP-1) market going forward. Personalized medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's genes or proteins. Personalized medicine allows for the tailoring of GLP-1 formulations and dosages based on individual patient needs and preferences. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing emphasis on personalized medicine is driving the growth of the glucagon-like peptide 1 (GLP-1) market.

Global Glucagon-like Peptide 1 Market Trends and Insights

Major companies operating in the glucagon-like peptide 1 market are focusing on developing technological advancements to enhance therapeutic efficacy, safety, and patient convenience in weight management and diabetes care. Glucagon-like peptide 1 (GLP-1) therapies are injectable peptide-based drugs that mimic the activity of the endogenous hormone GLP-1 to regulate appetite, glucose metabolism, and body weight. For instance, in March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly GLP-1 therapy for weight management. The therapy, developed through the STEP Phase 3a clinical trial program, demonstrated a safe and well-tolerated profile and is designed to help people with obesity achieve and maintain weight loss. By introducing a convenient weekly dosing regimen, Wegovy enhances patient adherence and addresses the growing demand for innovative, effective obesity treatments.

What Are Latest Mergers And Acquisitions In The Glucagon-like Peptide 1 Market?

In March 2024, Novo Holdings A/S, a Denmark-based investment company acquired Catalent Inc for $16.5 billion. With this acquisition, Novo Holdings aims to strengthen its footprint in the high-growth GLP-1 market by leveraging Catalent’s established infrastructure in fill-finish manufacturing, ensuring increased capacity to meet the rising demand for diabetes and weight-loss treatments. Catalent Inc is US-based biotechnology company specializes in advanced delivery technologies and development solutions for pharmaceuticals.

Regional Insights

North America was the largest region in the glucagon-like peptide 1 market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Glucagon-like Peptide 1 Market?

The glucagon-like peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glucagon-like Peptide 1 Market Report 2026?

The glucagon-like peptide 1 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide 1 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.